http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113527405-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 |
| filingDate | 2021-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113527405-B |
| titleOfInvention | Application of hedera saponin polyethylene glycol modified derivatives to prepare tumor drug resistance reversal agent |
| abstract | The invention discloses the application of hedera saponin polyethylene glycol modified derivatives to prepare tumor drug resistance reversing agent. The polyethylene glycol-modified derivatives of helexin and the optical isomers of the above-mentioned compounds or pharmaceutically acceptable solvates thereof. The effective amount of the compound or its salt and a pharmaceutically acceptable carrier are used in combination with commonly used clinical antitumor drugs to treat diseases or conditions such as oral epithelial cancer, gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer. Use of the helexin polyethylene glycol modified derivatives of the present invention and medically acceptable salts thereof for preparing tumor drug resistance reversing agents and/or pharmaceutically acceptable carriers for treating mammals, preferably treating human diseases or conditions . |
| priorityDate | 2021-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.